OBJECTIVES: The purpose of this study was to evaluate the biologic stability of mucosal parameters that might be used as endpoints in phase 1 rectal safety studies. METHODS: Sixteen male participants were enrolled into 4 groups defined by HIV status, viral load, and sexual activity. Each participant underwent 3 flexible sigmoidoscopies at 2-week intervals with collection of blood, intestinal biopsies, and rectal secretions. Intestinal histology, phenotypic characterization of mucosal mononuclear cells, cytokine messenger RNA (mRNA) profiles (RANTES, interferon-gamma [IFNgamma], and interleukin-10), and immunoglobulin secretion were assessed. Intraclass correlation (ICC) was calculated to assess endpoint stability. RESULTS: Qualitative histology demonstrated minimal inflammation in >95% of biopsies and remained stable throughout the study period. ICC for the tissue cytokine mRNA measurements and several T-cell phenotypic markers was >0.7, indicating stability over time. Mucosal CD4 lymphopenia was seen in the HIV-positive participants and was more pronounced in those with higher viral loads. Modest differences were observed for cytokine expression (IFNgamma) and T-cell phenotype (CD3, CD4, CD8, CD19, CD4/CCR5, and CD4/CD38) between the tissue samples collected at 10 and 30 cm. CONCLUSIONS: These data help to provide a rationale for the selection of endpoints for future phase 1 rectal safety studies.
OBJECTIVES: The purpose of this study was to evaluate the biologic stability of mucosal parameters that might be used as endpoints in phase 1 rectal safety studies. METHODS: Sixteen male participants were enrolled into 4 groups defined by HIV status, viral load, and sexual activity. Each participant underwent 3 flexible sigmoidoscopies at 2-week intervals with collection of blood, intestinal biopsies, and rectal secretions. Intestinal histology, phenotypic characterization of mucosal mononuclear cells, cytokine messenger RNA (mRNA) profiles (RANTES, interferon-gamma [IFNgamma], and interleukin-10), and immunoglobulin secretion were assessed. Intraclass correlation (ICC) was calculated to assess endpoint stability. RESULTS: Qualitative histology demonstrated minimal inflammation in >95% of biopsies and remained stable throughout the study period. ICC for the tissue cytokine mRNA measurements and several T-cell phenotypic markers was >0.7, indicating stability over time. Mucosal CD4 lymphopenia was seen in the HIV-positive participants and was more pronounced in those with higher viral loads. Modest differences were observed for cytokine expression (IFNgamma) and T-cell phenotype (CD3, CD4, CD8, CD19, CD4/CCR5, and CD4/CD38) between the tissue samples collected at 10 and 30 cm. CONCLUSIONS: These data help to provide a rationale for the selection of endpoints for future phase 1 rectal safety studies.
Authors: Bret J Rudy; Bill G Kapogiannis; Michelle A Lally; Glenda E Gray; Linda-Gail Bekker; Paul Krogstad; Ian McGowan Journal: J Acquir Immune Defic Syndr Date: 2010-07 Impact factor: 3.731
Authors: Jennifer Mait-Kaufman; Esra Fakioglu; Pedro M M Mesquita; Julie Elliott; Yungtai Lo; Rebecca Pellett Madan Journal: AIDS Res Hum Retroviruses Date: 2015-04-08 Impact factor: 2.205
Authors: Peter A Anton; F Javier Ibarrondo; W John Boscardin; Ying Zhou; Elissa J Schwartz; Hwee L Ng; Mary Ann Hausner; Roger Shih; Julie Elliott; Patricia M Hultin; Lance E Hultin; Charles Price; Marie Fuerst; Amy Adler; Johnson T Wong; Otto O Yang; Beth D Jamieson Journal: Vaccine Date: 2008-06-17 Impact factor: 3.641
Authors: Ian McGowan; Karen Tanner; Julie Elliott; Javier Ibarrondo; Elena Khanukhova; Charina McDonald; Terry Saunders; Ying Zhou; Peter A Anton Journal: AIDS Res Hum Retroviruses Date: 2012-09-04 Impact factor: 2.205